Echovirus polymyositis in patients with hypogammaglobulinemia

Crennan, Joan M.; Scoy, Robert E. Van; Mckenna, Charles H.; Smith, Thomas F.

doi:10.1016/0002-9343(86)90179-8

Cited by 33 publications

(1 citation statement)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Aseptic meningoencephalitis is a rare complication in patients with hypogammaglobulinemia and was first described by Linnemann et al (5) 15 years ago. The most common causative agent is echovirus ( 5 ) . However, in many cases no virus has been isolated from the cerebrospinal fluid (1).…”

mentioning

confidence: 99%

Immunoglobuttn Administration into Cerebral Subarachnoid Space in a Child with Hypogammaglobulinemia and Aseptic Meningoencephalitis

Benderly¹,

Pollack²

1988

Acta Paediatrica

View full text Add to dashboard Cite

mentioning

confidence: 99%

Immunoglobuttn Administration into Cerebral Subarachnoid Space in a Child with Hypogammaglobulinemia and Aseptic Meningoencephalitis

Benderly¹,

Pollack²

1988

Acta Paediatrica

View full text Add to dashboard Cite

High- vs Low-Dose Immunoglobulin Therapy in the Long-term Treatment of X-linked Agammaglobulinemia

Liese¹,

Wintergerst²,

Tympner³

et al. 1992

Arch Pediatr Adolesc Med

View full text Add to dashboard Cite

Historic aspects of intravenous immunoglobulin therapy

Good¹,

Lorenz²

1991

Cancer

View full text Add to dashboard Cite

The earliest preparations of immunoglobulins (Ig) decreased the susceptibility of agammaglobulinemic patients to infections caused by pneumococci, Haemophilus influenzae, meningococci, streptococci, and Pseudomonas aeruginosa. Intramuscular administration of such preparations was painful and traumatic, especially for children. Ethanol‐fractionated Ig could not be administered intravenously (IV) because the IgG molecules tended to aggregate and thus were more likely to produce anaphylactoid reactions. New Ig preparations, isolated at low pH (e.g., pH 4) in the presence of traces of pepsin to inhibit reaggregation, were well tolerated when administered IV. Thus a new era of treatment and prophylaxis of disease using IV Ig (IVIG) was launched. The IVIG preparations revolutionized the management of virtually all immunodeficiency syndromes characterized by failure of antibody responses. Amelioration of antibody deficiency secondary to certain chronic diseases or surgical trauma can be achieved with these preparations. Newer uses of IVIG include treatment of some autoimmune diseases; in some conditions, the beneficial influences may be attributable to antiidiotype antibodies present in the IVIG. Another likely explanation is that IVIG inhibits damage to cells and tissues by antibody‐mediated cellular cytotoxicity or blocks phagocytosis that is facilitated by Fc receptor mechanisms. The value of IVIG in preventing infection in patients undergoing bone marrow or organ transplantation and in the treatment and prophylaxis of life‐threatening infections in neonates and premature infants also is reviewed.

show abstract

Echovirus polymyositis in patients with hypogammaglobulinemia

Cited by 33 publications

References 17 publications

Immunoglobuttn Administration into Cerebral Subarachnoid Space in a Child with Hypogammaglobulinemia and Aseptic Meningoencephalitis

Immunoglobuttn Administration into Cerebral Subarachnoid Space in a Child with Hypogammaglobulinemia and Aseptic Meningoencephalitis

High- vs Low-Dose Immunoglobulin Therapy in the Long-term Treatment of X-linked Agammaglobulinemia

Historic aspects of intravenous immunoglobulin therapy

Contact Info

Product

Resources

About